Thursday, September 10, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight

View original at globenewswire.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight New York, USA, June 08, 2026 (GLOBE NEWSWIRE) -- Alcohol Use Disorder Market Set to Expand at a 12.1% CAG…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Growing awareness, early AUD diagnosis, rising focus on harm reduction and personalized care, and strong clinical trial activity are expected to drive significant AUD market growth

    60% confidence

  • There were 25.6 million 12-months diagnosed prevalent cases of AUD in the US in 2025, which are projected to decrease by 2036

    60% confidence

  • The United States accounted for the largest alcohol use disorder treatment market size in 2025 compared to EU4, UK, and Japan

    60% confidence

  • The 12-month diagnosed prevalence of AUD in the US declined from approximately 10.6% in 2021 to approximately 9.7% in 2025

    60% confidence

  • The AUD market is projected to expand at a 12.1% CAGR during the forecast period 2026–2036

    60% confidence

  • Brenipatide represents Eli Lilly's expansion into indications beyond obesity, including alcohol use disorder, opioid dependence, and asthma

    60% confidence

  • VIVITROL (naltrexone) holds the highest US AUD market share in 2025, while by 2036, AD04 is projected to capture the largest market

    60% confidence

  • The exploration of novel mechanisms in AUD treatment such as 5-HT3 antagonism, NOP receptor modulation, mGluR5 NAM activity, and dual GLP-1/glucagon receptor agonism highlights significant opportunities for other developers to enter a space with high unmet need and to differentiate their pipelines through innovative, non-traditional targets

    60% confidence

  • Although several AUD therapies have been approved, treatment uptake remains substantially low, leaving a significant proportion of affected individuals untreated

    60% confidence

  • Altimmune expects to announce topline results from the RECLAIM Phase II trial evaluating pemvidutide in AUD in 2026

    60% confidence

  • The AUD market size was USD 1.1 billion across the 7MM in 2025

    60% confidence

  • The AD04 patent, once granted, is expected to protect Adial's core assets through at least 2045

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Boom Meets Valuation Jitters: Funding Surges While Bellwether Stocks Wobble
A dense wave of AI-sector funding (Socure, Stability AI, Emerald AI, Generalist AI, Gatik, Regent Craft and others closing rounds on the same day) and strong enterprise-automation earnings (UiPath raising full-year guidance) point to continued heavy capital deployment into AI infrastructure, fintech-adjacent AI, and agentic automation. Yet Palantir's stock fell even after winning the Army's high-profile TITAN contract, and commentary (e.g., the Alphabet bull case citing AI capex and regulatory risk) signals growing investor unease about whether current AI valuations and spending levels are sustainable.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,278 source documents archived
Query this data → isubstrate.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight — Source | Via News | ViaNews Market